GlobeNewswire

Myriad Genetics Reports Third Quarter 2026 Financial Results; Raises Mid-Point of Full-Year 2026 Revenue Guidance Following Solid Execution Definitive Agreement to Sell Prenatal Health Business to Support Strategic Growth Initiatives
04/11/2026
Highl ights Third quarter 2026 revenue was $202.7 million, representing a 6% sequential increase and a 1% decrease year-over-year. Higher Cancer Care Continuum (CCC) product mix and continued progress on payer [...]
LeMaitre Q3 2026 Financial Results
04/11/2026
BURLINGTON, Mass., Nov. 04, 2026 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq: LMAT), a provider of vascular devices, implants, and services, today reported Q3 2026 results, announced a quarterly dividend of $0. [...]
Tenaya Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update
04/11/2026
Received Regenerative Medicine Advanced Therapy (RMAT) Designation from U.S. FDA for TN-401 Gene Therapy for PKP2-Associated Arrhythmogenic Right Ventricular Cardiomyopathy TN-201 and TN-401 Program Updates on Upcoming [...]
Agomab to Participate in Upcoming Investor Conferences
04/11/2026
Antwerp, Belgium, November 4, 2026 – Agomab Therapeutics NV (Nasdaq: AGMB) (“Agomab”), a clinical-stage biopharmaceutical company focused on fibro-inflammation, today announced that members of the management team will [...]
Revolution Medicines Reports Third Quarter 2026 Financial Results and Update on Corporate Progress
04/11/2026
Received U.S. FDA approval and launched RASONQUE ® (daraxonrasib) for adult patients with metastatic pancreatic cancer who have received at least one prior systemic therapy or who are not candidates for multiagent [...]
Baird Medical Issues Statement Regarding Recent Share Price Volatility
04/11/2026
NEW YORK, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Baird Medical Investment Holdings Limited (NASDAQ: BDMD) (“Baird Medical” or the “Company”), a healthcare innovator dedicated to microwave ablation (MWA) technology, has [...]
New Research Suggests hERG IC₁₀ May Improve Prediction of Drug-Induced QT Prolongation
04/11/2026
NEW ORLEANS, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Dr. William J. Crumb Jr., Ph.D., President and CEO of Nova Research Laboratories, LLC, has collaborated with Dr. Andrew G. Edwards, Ph.D., Chief Research Scientist of [...]
Guidepoint Qsight Launches Consumer Sentiment Tool to Understand Motivations, Behavior & Trends in Aesthetics
04/11/2026
New York, NY, Nov. 04, 2026 (GLOBE NEWSWIRE) -- New Qsight Platform Provides Powerful Insights into Both Current and Prospective Patients in the Medical Aesthetics Market Captures the total addressable market, both [...]
Hennick Humber Hospital Opened Its Doors to 150 Students to Explore the Future of Healthcare
04/11/2026
Annual Take Our Kids to Work Day experience gave young people a firsthand look at the people, technology and career possibilities shaping modern healthcare TORONTO, Nov. 04, 2026 (GLOBE NEWSWIRE) -- What did the future [...]
Pacific Health Care Organization, Inc. Reports its Third Quarter 2026 Financial Results
04/11/2026
Irvine, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Pacific Health Care Organization, Inc., (the “Company”) (OTCQB: PFHO) filed yesterday with the Securities and Exchange Commission (the “SEC”) its quarterly report on Form 10-Q [...]
Neion Bio Taps John Maga as Head of Biologics and CMC to Expand Capabilities In Innovative Development
04/11/2026
Veteran biopharmaceutical executive brings deep experience across complex therapeutic modalities as Neion expands the Raptor platform for innovative and difficult-to-express proteins NEW YORK, Nov. 04, 2026 (GLOBE [...]
Standard Dental Labs Acquires M&D Dental Arts; Announces December 1 Launch Target for Bridge AI Software
04/11/2026
Acquisition expected to double Orlando laboratory output; internally developed platform connects digital dentistry workflows and lays groundwork for AI-assisted restoration design ORLANDO, Fla., Nov. 04, 2026 (GLOBE [...]
Valneva to Report Nine-Month 2026 Consolidated Financial Results on November 24, 2026
04/11/2026
Lyon (France), November 4, 2026 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that it will report its nine-month 2026 financial results on Tuesday, November 24, 2026. The [...]
Valneva publiera ses résultats financiers consolidés des neuf premiers mois de l’année le 24 novembre 2026
04/11/2026
Lyon (France), le 4 novembre 2026 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), société spécialisée dans les vaccins, a annoncé aujourd'hui qu’elle publiera ses résultats financiers des neuf premiers mois de l’année [...]
Virbac : Declaration of the number of shares and voting rights 10/2026
04/11/2026
DECLARATION OF THE NUMBER OF SHARES AND VOTING RIGHTS Information on the total number of voting rights and of shares representing the share capital (Article 223-16 of the General regulations of the French Financial [...]
Virbac : Déclaration d'actions et de droits de vote 10/2026
04/11/2026
DÉCLARATION D’ACTIONS ET DE DROITS DE VOTE Informations relatives au nombre total de droits de vote et au nombre d’actions composant le capital (Article 223-16 du Règlement Général de l’Autorité des Marchés Financiers) [...]
Tessera Therapeutics to Present New Preclinical Data Supporting its In Vivo Sickle Cell Disease Program and In Vivo CAR-T Applications at the 68th American Society of Hematology Annual Meeting
04/11/2026
SOMERVILLE, Mass., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Tessera Therapeutics, Inc. (“Tessera”), a clinical-stage biotechnology company pioneering a new approach in genetic medicine known as Gene Writing™, today announced [...]
Zelluna ASA awarded NOK 15.6 million Research Council of Norway grant to further advance TCR-NK manufacturing
04/11/2026
Oslo, 4 November 2026 – Zelluna (OSE: ZLNA), a company pioneering allogeneic “off-the-shelf” T Cell Receptor-based Natural Killer (TCR-NK) cell therapies for the treatment of solid cancers, today announced that the [...]
Asgard Therapeutics announces publication in Immunity demonstrating induction of cancer-fighting tertiary lymphoid structures across seven tumor types – and will present new AT-108 biomarker data at SITC 2026
04/11/2026
Study in Immunity highlights Asgard's ability to generate potent immunogenic tertiary lymphoid structures (imgTLSs) solely by reprogramming tumor cells into antigen-presenting conventional type 1 dendritic cells (cDC1s [...]

Pages

Other news

Test 2

Lorem ipsum

Test 1

Lorem upsum